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Objectives: Activation of the neuroendocrine axis in congestive heart failure is of
prognostic significance, and neurohumoral blocking therapy prolongs survival. The
hypothesis that surgical reduction of left ventricular size and function decreases
neuroendocrine activation is less established. We evaluated the neurohormonal
response to left ventricular reconstruction surgery in ischemic cardiomyopathy.
Methods: Norepinephrine, plasma renin activity, and angiotensin II were measured
in 10 patients before and 12 months after left ventricular reconstruction. In an
additional 5 patients, brain natriuretric peptide was measured before and 3 months
postoperatively. Three-dimensional cardiovascular imaging was used to assess
ejection fraction and left ventricular end-diastolic volume index.
Results: Concurrent with improvements of New York Heart Association functional
class (2.9  0.5 preoperatively vs 2.0  0.4 postoperatively, P  .001), ejection
fraction (23.9%  6.6% vs 36.2%  6.2%, P  .01), and left ventricular end-
diastolic volume index (140.8  33.8 mL/m2 vs 90.6  18.3 mL/m2, P  .01),
considerable reductions were observed for median plasma profiles of norepinephrine
(562.0 pg/mL vs 319.0 pg/mL, P  .05), plasma renin activity (5.75 g/L/h vs 3.45
g/L/h, P  .05), angiotensin II (41.0 ng/mL vs 23.0 ng/mL, P  .051), and brain
natriuretric peptide (771.0 pg/mL vs 266.0 pg/mL, P .05). The more plasma renin
activity or angiotensin II decreased after left ventricular reconstruction, the higher
was the increase in ejection fraction (R  .745, P  .05 [plasma renin activity];
R  .808, P  .05 [angiotensin II]).
Conclusions: Surgical improvements of ejection fraction and left ventricular end-
diastolic volume index by left ventricular reconstruction were accompanied by
improvement of both the neuroendocrine activity and the functional status in
patients with congestive heart failure. Whether this favorable neurohormonal re-
sponse is predictive of an improved survival requires further evaluation.
Myocardial infarction is a common cause of congestive heartfailure (CHF).1 Following injury, ventricular remodeling en-sues, resulting in infarct expansion, left ventricular (LV)enlargement, and occasionally aneurysm formation.2 Con-comitant activation of neurohumoral systems occurs and is ofprognostic importance.3 Increased plasma norepinephrine
(NE) and plasma renin activity (PRA) are historically associated with poor surviv-
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al.4 Plasma angiotensin II (A-II) is elevated in patients with
CHF.5 Plasma brain natriuretric peptide (BNP) is increased
in patients with CHF and also predicts long-term survival
after myocardial infarction.6-8 Neuroendocrine activation
can be altered by neurohumoral blocking therapy (beta-
blockers and angiotensin-converting enzyme [ACE] inhib-
itors), reducing mortality in CHF.9,10
LV reconstruction (LVR) surgery effectively treats CHF
due to ischemic cardiomyopathy by removing nonviable,
scarred tissue and restoring more normal ventricular geom-
etry.11 We hypothesized that surgical intervention would
initiate beneficial LV remodeling. If prognosis is improved,
there should also be reduced neurohumoral activation. We
analyzed the level of neuroendocrine activation before and
up to 1 year after LVR surgery and we present the results
here.
Materials and Methods
Patients
Plasma levels of NE, PRA, and A-II were measured before (base-
line) and 12 months after LVR in 10 patients. Criteria for study
enrollment were anticipated LVR surgery judged as previously
described,11 the agreement to return for all scheduled follow-up
visits, and informed consent in compliance with the Institutional
Review Board at The Cleveland Clinic Foundation. Three addi-
tional patients were originally recruited but could not return to our
institution for a follow-up visit because they moved to a remote
location. They were omitted from this study. Plasma BNP was
measured in 5 additional patients before and 3 months after sur-
gery. All patients (7 women, 8 men; age 60.7  11.8 years)
received optimized medical therapy for heart failure, consisting of
ACE inhibitors, beta-blockers, diuretics, spironolactone, and
digoxin (Table 1). Blood tests were drawn the same day as either
real-time 3-dimensional echocardiography (RT3DE) or magnetic
resonance imaging (MRI). We have previously shown that RT3DE
and MRI not only accurately reflect the geometry in LV aneurysms
but also reproduce LV volumes and ejection fraction (EF) with
excellent correlation and agreement.12,13 Pre- and postoperative
assessment of LV function by RT3DE and/or MRI was available in
13 patients; 2 patients had only preoperative cardiovascular imag-
ing.
Surgical Technique
Normothermic cardiopulmonary bypass was used in all patients.
First, adjunct procedures, for example, coronary artery bypass
grafting (CABG) and/or repair of the mitral valve (MVR), were
performed under cardioplegic arrest. LV reconstruction was per-
formed on the beating heart.14 The LV aneurysm was opened and
adherent thrombi were removed. Any subendocardial scar on the
septum and anterior LV wall was resected, and the border zone
between infarcted and normal myocardium was identified. Two
circular polypropylene purse-string sutures were placed, creating a
neck and obliterating the orifice. The ventriculotomy was closed
by a horizontal mattress suture. Intraoperative echocardiography
was used to assess the appropriate LV cavity size.15 Surgical
details are summarized in Table 2.
Quantitative 3-Dimensional Imaging
An RT3DE system (Volumetrics Medical Imaging, Inc, Durham,
NC) or MRI (Siemens Vision, Erlangen, Germany) was used to
determine LV end-diastolic (LVEDV) and end-systolic (LVESV)
volumes13,16 and to calculate EF, LVEDV index (LVEDVI), and
LVESV index (LVESVI).
Neurohormone Assays
Venous blood samples were obtained with the patient in the supine
position after 30 minutes of rest and immediately transferred to
chilled tubes. NE (normal range 80-520 pg/mL), PRA (normal
range 0.5-1.8 g/L/h), and BNP (normal range100 pg/mL) were
measured at our institution; additional probes were sent on dried
ice to Quest Diagnostics (San Juan Capistrano, Calif) for measure-
ment of A-II (normal range 10-50 ng/L).
Statistical Analysis
Data were expressed as median, mean, and 95% confidence inter-
val. Neurohormones, cardiovascular function, and New York
Heart Association (NYHA) functional class were compared by a
Wilcoxon signed-rank test. The association between neurohor-
mones and LV function was evaluated by Pearson’s correlation
test. All analyses were performed with SPSS 11.5 (SPSS Inc,
Chicago, Ill).
TABLE 1. Medications (n  15)
Medication Preoperative Postoperative*
Beta-blocker 12 (80%) 12 (80%)
ACE inhibitor 14 (93%) 14 (93%)
Diuretic 10 (67%) 10 (67%)
Spironolactone 4 (27%) 6 (40%)
Digoxin 13 (87%) 8 (53%)
ACE, Angiotensin-converting enzyme.
Data presented as number (%) of patients.
*Time of postoperative follow-up varied from 3 months (5 patients) to 12
months (10 patients). No difference was observed between groups. Indi-
vidual dosages of beta-blockers, ACE inhibitors, and diuretics were in-
creased after surgery in 4, 1, and 1 patients, respectively; were decreased
in 2, 4, and 4 patients; respectively; and were unchanged in 6, 9, and 5
patients, respectively.
TABLE 2. Surgical details (n  15)
Aneurysm location (anterior/posterior) 15/0
Wall movement (dyskinetic/akinetic) 13/2
Primary/patch closure of
endoaneurysmorrhaphy
14/1
CABG 11
Number of grafts 2.2 1.0
Utilization of arterial grafts 73%
Mitral valve repair 5
Tricuspid valve repair 2
Cryoablation 2
CABG, Coronary artery bypass grafting.
Data presented as mean  SD or number (%) of patients.
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Results
LVR Surgery
The procedure was well tolerated in all 15 patients. Before
LVR surgery, 3 patients were in NYHA functional class II,
11 patients in class III, and 1 patient in class IV. NYHA
class improved in 13 patients whereas 2 patients had no
change (1 patient in class I, 13 patients in class II, and 1
patient in class III [P  .001]; Figure 1). Medical heart
failure treatment was similar to preoperative therapy (Table
1); routine laboratory tests did not detect hepatic or renal
dysfunction in any patient.
LV Function
EF increased from 23.9%  6.6% to 36.2%  6.2% (P 
.003) (Table 3). LVEDVI and LVESVI decreased from
140.8  33.8 mL/m2 to 90.6  18.3 mL/m2 (P  .005) and
from 107.6  30.9 mL/m2 to 57.6  12.7 mL/m2 (P 
.003), respectively. Mitral regurgitation, present preopera-
tively in 5 patients, was also decreased. There was no
difference in EF, LVEDVI, or LVESVI between the 10
patients followed for 12 months and the 5 patients followed
for 3 months, confirming our previous observation that
improvement of LV function evolved intraoperatively/early
postoperatively and was sustained late after LVR.16
Neurohormones
Plasma levels of NE, PRA, A-II, and BNP significantly
improved after LVR (Table 4). Median NE decreased from
562 pg/mL to 319 pg/mL (P  .05). Median PRA and
median A-II dropped from 5.7 g/L/h to 3.4 g/L/h (P 
.05) and from 41 ng/mL to 23 ng/mL (P  .051), respec-
tively. Median BNP decreased from 771 pg/mL to 266
pg/mL (P  .05). Figure 2 depicts the course of NE, PRA,
and A-II in each patient.
The changes of pre- to postoperative PRA and A-II
inversely correlated with the change of EF. The more PRA
decreased after surgery, the higher the increase of EF (R 
.745, P  .05). A similar association was found between
the decrease of A-II and the increase of EF (R  .808, P
 .05). Furthermore, the decrease of BNP correlated with
the decrease of LVEDVI with a trend toward significance (R
 .846, P  .071). No association was found between
changes of NE and changes of EF, LVEDVI, or LVESVI.
Discussion
Neuroendocrine Activation in CHF
Neurohormones participate in many pathologic adaptations
and can contribute to the progression of CHF.17 Medical
therapy that decreases neuroendocrine activation also re-
duces the mortality of CHF9,10,18 and may correlate with
modest improvements of EF and functional parameters.19-21
However, neurohormonal models may be necessary but are
not sufficient to explain all aspects of disease progression in
CHF.22 Neurohormones are not deranged without a trigger-
ing event; thus the elimination of 1 trigger (eg, surgical
reduction of pathologic cardiac wall stress) may result in the
reduction of neurohormones. In support of this, lowering
cardiac filling pressure alone by diuretics and vasodilators
can rapidly suppress the neurohumoral activation in decom-
pensated heart failure with decreased BNP and NE pro-
files.23
Neurohormonal Response to Surgical Intervention
In this study, we observed improvement in neurohormones
that may be attributed to surgical improvement of LV anat-
omy with increase of EF and decrease of LV volume and
mitral regurgitation. Importantly, although LVR was an
aspect of additional procedures (eg, CABG or MVR), the
impact of each individual surgical therapy on the improve-
ment of neurohormones cannot be determined because all
associated aspects of ischemic cardiomyopathy were re-
paired. We and others24,25 advocate a complete revascular-
ization whenever possible to achieve an optimal result after
LVR. Valve repair, if necessary, is also indicated to realize
the full benefit of this procedure.26 We expect that the
favorable neurohormonal response observed in this study
may have been generated by the combined surgical strategy.27
In agreement with the current study, atrial natriuretric
peptide (ANP) and BNP profiles were significantly lowered
after revascularization in ischemic cardiomyopathy concur-
rent with an improvement of LV function and NYHA func-
tional class.28 We have previously shown that the insertion
of an LV assist device in patients with decompensated CHF
was followed by significantly improved NE, PRA, and A-II
profiles, concomitant with partial recovery of the native
heart.29 Furthermore, preoperatively elevated plasma ANP
levels normalized after mitral valve surgery for degenera-
Figure 1. NYHA functional class (mean) before and after surgery
(n  15). Time of postoperative follow-up varied from 3 months (5
patients) to 12 months (10 patients). No difference was observed
between groups. NYHA FC, New York Heart Association func-
tional class.
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tive valve disease along with an improvement of functional
parameters.30
Implications
The favorable neurohormonal response observed in this
study may indicate an improved long-term prognosis after
LVR surgery. Patients with a considerable percent decrease
in NE (and BNP) profiles may experience a profound de-
cline in mortality.31 Further, median NE levels above 393
pg/mL were previously found predictive for an increased
mortality.32 In our study, median NE was significantly re-
duced to 319 pg/mL, a profile similar to that of a matching
cohort of control subjects in the SOLVD trial.3 This obser-
vation suggests that the mortality of patients with ischemic
cardiomyopathy can be significantly reduced by surgery
including LVR. In addition, depressed EF (30%) and
increased LVESVI (70 mL/m2) were associated with an
increased mortality of patients with myocardial infarction33
and CHF.34 In this study, baseline EF and LVESVI were
even more compromised; thus, the improvement of both
parameters by LVR surgery to 36.2%  6.2% and 57.6 
12.7 mL/m2, respectively, may also prognosticate a better
long-term survival. Moreover, PRA and A-II profiles, both
markedly reduced by LVR in this study, were elevated in
patients with poor LV function and overt CHF.3,35 Accord-
ingly, we found an inverse correlation between changes of
PRA and A-II profiles with changes of EF in the current
study. Furthermore, the decrease of BNP profiles after LVR
in this study may not only be predictive of a reduced
mortality6,7,31,36 but may also indicate the suppression of a
trigger of neuroendocrine activation. In agreement with the
current study, previous reports have shown that BNP is
related to LVEDVI36 and the reduction of intracardiac fill-
ing pressure decreases BNP profiles.23 Reduction of cardiac
wall stress may possibly contribute to the decreased neu-
roendocrine activation after LVR.
Study Limitations
This study analyzed the effect of LVR surgery on neuroen-
docrine activation in a small number of patients. Impor-
tantly, the improvement of LV function in the patients
studied is in close agreement with previous reports of larger
cohorts of patients from our institution12-16 and elsewhere,11
indicating that the patients enrolled in this study are indeed
representative. Continued medical therapy, while un-
changed from preoperative therapy, may have contributed
to the improvement of neurohormones in addition to the
surgical therapy.
Another limitation arises from the different lengths of
follow-up in the 5 patients with BNP profiles in comparison
with the remaining 10 patients with other neurohormone
data. Of note, improvements of LV function and NYHA
classification did not differ between groups, suggesting that
the trigger of the neurohormonal response was similar and,
hence, the course of neurohormone profiles were likely
comparable. LV redilation years after surgery may be pos-
sible and could lead to reactivation of neurohormones with
consecutive decrease of prognosis.
TABLE 3. Left ventricular ejection fraction and dimensions, mitral regurgitation (n  15)*
Preoperative Postoperative‡ Mean % change P value
Ejection fraction (%) 23.9 6.6 36.2 6.2 51.5 .003
End-diastolic volume index (mL/m2) 140.8 33.8 90.6 18.3 35.6 .005
End-systolic volume index (mL/m2) 107.6 30.9 57.6 12.7 46.5 .003
Mitral regurgitation† (grade) 2.4 1.5 0.8 1.1 N/A .035
*Left ventricular volumes and ejection fraction were assessed by magnetic resonance imaging, real-time 3-dimensional echocardiography, or a
combination of both. Magnetic resonance was assessed by 2-dimensional echocardiography.
†Data are presented for 5 patients undergoing mitral valve repair.
‡Time of postoperative follow-up varied from 3 months (5 patients) to 12 months (10 patients). No difference was observed between groups.
TABLE 4. Neurohormones
Preoperative Postoperative* Mean %
change P valueMedian (n) Mean (95% CI) Median (n) Mean (95% CI)
Norepinephrine (pg/mL) (80-520 pg/mL) 562 (10) 616 (377; 855) 319 (10) 406 (223; 591) 34.0 .017
Plasma renin activity (g/L/h) (0.5-1.8
g/L/h)
5.7 (10) 13.6 (4.0; 23.2) 3.4 (10) 4.8 (2.0; 7.7) 64.7 .022
Angiotensin II (ng/mL) (10-50 ng/L) 41 (9) 92 (0; 206) 23 (10) 29 (14; 44) 68.3 .051
Brain natriuretric peptide (pg/mL)
(100 pg/mL)
771 (5) 776 (373; 1178) 266 (5) 417 (83; 750) 46.3 .043
*Time of postoperative follow-up varied from 3 months (brain natriuretric peptide) to 12 months (norepinephrine, plasma renin activity, angiotensin II).
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Conclusions
LVR surgery was accompanied by a favorable neurohor-
monal response. Decreased profiles of selected neurohor-
mones were associated with improved LV function. These
results support the hypothesis that direct improvement of
cardiovascular function may reduce neuroendocrine activa-
tion by removing trigger mechanisms. Because neuroendo-
crine activation is of prognostic significance in CHF, the
favorable neurohormonal response after LVR surgery may
be indicative of an improved long-term survival. Further
studies are necessary to confirm this prediction.
The authors thank Ms Adelaide Jaffe for editorial advice.
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